Immunotherapy of metastatic kidney cancer

Giancarlo Pizza; Caterina De Vinci; Giuseppe Lo Conte; Paolo Maver; Ennio Dragoni; Ernesto Aiello; Vittorio Fornarola; Tiziano Bergami; Luciano Busutti; Stefano Boriani; Aldopaolo Palareti; Rodolfo Capanna

doi:10.1002/ijc.1426

Immunotherapy of metastatic kidney cancer

Giancarlo Pizza, Caterina De Vinci, Giuseppe Lo Conte, Paolo Maver, Ennio Dragoni, Ernesto Aiello, Vittorio Fornarola, Tiziano Bergami, Luciano Busutti, Stefano Boriani, Aldopaolo Palareti, Rodolfo Capanna

Istituti Ortopedici Rizzoli

Research output: Contribution to journal › Article › peer-review

Abstract

From April 1986 to September 2000, 122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 × 10⁶ LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy (n = 89) represent our historical controls. Adverse clinical side effects related to treatment were negligible. CR (n = 11) and PR (n = 13) were noticed in 24/122 patients. Of 24 responding patients, 17 resumed progression, whereas 7 remain in remission 11-69 months later. The overall median survival of treated patients (28 months) was 3.5-fold higher than the median survival of historical controls (7.5 months), and a Kaplan-Meier curve showed 25% survival 11 years after the beginning of immunotherapy. Apparently, the addition of IL-2 by inhalation improved survival. The present immunotherapy protocol appears to be efficacious, safe, devoid of adverse side effects, far less costly than others and able to offer a good quality of life to MRCC patients; if confirmed in a multicenter trial, it could set the basis for developing low-dose immunomodulatory treatments.

Original language	English
Pages (from-to)	109-120
Number of pages	12
Journal	International Journal of Cancer
Volume	94
Issue number	1
DOIs	https://doi.org/10.1002/ijc.1426
Publication status	Published - Oct 1 2001

Keywords

IL-2
Immunotherapy
Interferon
Lymphokine-activated killer cells
Metastasis
Renal cancer
Transfer factor

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1002/ijc.1426

Cite this

@article{5cbe0ada312c4a52a338689b7521c3d4,

title = "Immunotherapy of metastatic kidney cancer",

abstract = "From April 1986 to September 2000, 122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 × 106 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy (n = 89) represent our historical controls. Adverse clinical side effects related to treatment were negligible. CR (n = 11) and PR (n = 13) were noticed in 24/122 patients. Of 24 responding patients, 17 resumed progression, whereas 7 remain in remission 11-69 months later. The overall median survival of treated patients (28 months) was 3.5-fold higher than the median survival of historical controls (7.5 months), and a Kaplan-Meier curve showed 25% survival 11 years after the beginning of immunotherapy. Apparently, the addition of IL-2 by inhalation improved survival. The present immunotherapy protocol appears to be efficacious, safe, devoid of adverse side effects, far less costly than others and able to offer a good quality of life to MRCC patients; if confirmed in a multicenter trial, it could set the basis for developing low-dose immunomodulatory treatments.",

keywords = "IL-2, Immunotherapy, Interferon, Lymphokine-activated killer cells, Metastasis, Renal cancer, Transfer factor",

author = "Giancarlo Pizza and {De Vinci}, Caterina and Conte, {Giuseppe Lo} and Paolo Maver and Ennio Dragoni and Ernesto Aiello and Vittorio Fornarola and Tiziano Bergami and Luciano Busutti and Stefano Boriani and Aldopaolo Palareti and Rodolfo Capanna",

year = "2001",

month = oct,

day = "1",

doi = "10.1002/ijc.1426",

language = "English",

volume = "94",

pages = "109--120",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Immunotherapy of metastatic kidney cancer

AU - Pizza, Giancarlo

AU - De Vinci, Caterina

AU - Conte, Giuseppe Lo

AU - Maver, Paolo

AU - Dragoni, Ennio

AU - Aiello, Ernesto

AU - Fornarola, Vittorio

AU - Bergami, Tiziano

AU - Busutti, Luciano

AU - Boriani, Stefano

AU - Palareti, Aldopaolo

AU - Capanna, Rodolfo

PY - 2001/10/1

Y1 - 2001/10/1

N2 - From April 1986 to September 2000, 122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 × 106 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy (n = 89) represent our historical controls. Adverse clinical side effects related to treatment were negligible. CR (n = 11) and PR (n = 13) were noticed in 24/122 patients. Of 24 responding patients, 17 resumed progression, whereas 7 remain in remission 11-69 months later. The overall median survival of treated patients (28 months) was 3.5-fold higher than the median survival of historical controls (7.5 months), and a Kaplan-Meier curve showed 25% survival 11 years after the beginning of immunotherapy. Apparently, the addition of IL-2 by inhalation improved survival. The present immunotherapy protocol appears to be efficacious, safe, devoid of adverse side effects, far less costly than others and able to offer a good quality of life to MRCC patients; if confirmed in a multicenter trial, it could set the basis for developing low-dose immunomodulatory treatments.

AB - From April 1986 to September 2000, 122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 × 106 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy (n = 89) represent our historical controls. Adverse clinical side effects related to treatment were negligible. CR (n = 11) and PR (n = 13) were noticed in 24/122 patients. Of 24 responding patients, 17 resumed progression, whereas 7 remain in remission 11-69 months later. The overall median survival of treated patients (28 months) was 3.5-fold higher than the median survival of historical controls (7.5 months), and a Kaplan-Meier curve showed 25% survival 11 years after the beginning of immunotherapy. Apparently, the addition of IL-2 by inhalation improved survival. The present immunotherapy protocol appears to be efficacious, safe, devoid of adverse side effects, far less costly than others and able to offer a good quality of life to MRCC patients; if confirmed in a multicenter trial, it could set the basis for developing low-dose immunomodulatory treatments.

KW - IL-2

KW - Immunotherapy

KW - Interferon

KW - Lymphokine-activated killer cells

KW - Metastasis

KW - Renal cancer

KW - Transfer factor

UR - http://www.scopus.com/inward/record.url?scp=17944377947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944377947&partnerID=8YFLogxK

U2 - 10.1002/ijc.1426

DO - 10.1002/ijc.1426

M3 - Article

C2 - 11668485

AN - SCOPUS:17944377947

SN - 0020-7136

VL - 94

SP - 109

EP - 120

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 1

ER -

Immunotherapy of metastatic kidney cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this